Zacks Investment Research downgraded shares of BIOLASE (NASDAQ:BIOL) from a buy rating to a hold rating in a research note issued to investors on Wednesday, reports.

According to Zacks, “Biolaw Technology, Inc. is the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets. “

BIOL has been the topic of several other reports. Benchmark began coverage on shares of BIOLASE in a research report on Wednesday, June 19th. They set a speculative buy rating and a $2.00 target price on the stock. Dougherty & Co reiterated a buy rating on shares of Iteris in a research report on Tuesday, April 30th.

NASDAQ:BIOL traded down $0.19 during mid-day trading on Wednesday, hitting $1.70. 59,700 shares of the company’s stock were exchanged, compared to its average volume of 44,652. The stock’s 50 day moving average is $1.63. The company has a debt-to-equity ratio of 1.56, a current ratio of 1.91 and a quick ratio of 1.11. BIOLASE has a fifty-two week low of $0.91 and a fifty-two week high of $2.87. The company has a market cap of $37.45 million, a price-to-earnings ratio of -2.00 and a beta of 2.01.

BIOLASE (NASDAQ:BIOL) last posted its earnings results on Thursday, May 9th. The medical technology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.05. BIOLASE had a negative net margin of 46.05% and a negative return on equity of 120.91%. The business had revenue of $10.33 million for the quarter, compared to the consensus estimate of $10.52 million. On average, analysts forecast that BIOLASE will post -0.59 earnings per share for the current year.

In other BIOLASE news, major shareholder Larry N. Feinberg sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $1.50, for a total transaction of $1,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.50% of the stock is currently owned by company insiders.


BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Read More: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on BIOLASE (BIOL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.